WAY 100,635 enhances both the 'antidepressant' actions of duloxetine and its influence on dialysate levels of serotonin in frontal cortex

被引：37

作者：

Millan, MJ ^{[1
]}

Brocco, M ^{[1
]}

Veiga, S ^{[1
]}

Cistarelli, L ^{[1
]}

Melon, C ^{[1
]}

Gobert, A ^{[1
]}

机构：

[1] IDRS, F-78290 Croissy Sur Seine, France

来源：

EUROPEAN JOURNAL OF PHARMACOLOGY | 1998年 / 341卷 / 2-3期

关键词：

serotonin reuptake inhibitor; frontal cortex; antidepressant; 5-HT1A receptor; 5-HT; (5-hydroxytryptamine; serotonin); depression;

D O I：

10.1016/S0014-2999(97)01445-3

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The mixed serotonin and noradrenaline reuptake inhibitor, duloxetine, (5.0 mg/kg, s.c.), increased levels of serotonin (220%), dopamine (180%) and noradrenaline (470%) in individual dialysates of frontal cortex of freely moving rats. Its influence on serotonin, but not dopamine or noradrenaline, levels was enhanced by the 5-HT1A receptor antagonist, WAY 100,635 (N-{2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl}-N-(2-pyridinyl) cyclo-hexanecarboxamide 3HCl) (0.16 mg kg(-1), s.c). In the forced swimming test, although duloxetine was inactive alone, it dose dependently reduced immobility in the presence of WAY 100,635. Thus, blockade of 5-HT1A (auto)receptors selectively facilitates the influence of duloxetine on serotonin levels in the frontal cortex in rats and, in the forced swimming model,enhances its "antidepressant" properties in parallel. (C) 1998 Elsevier Science B.V.

引用

页码：165 / 167

页数：3

共 10 条

[1] Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists [J].